By Michael Calia
Mylan Inc. (MYL) said Thursday that a jury ruled in its favor
against GlaxoSmithKline PLC (GSK) in a breach-of-contract
lawsuit.
The jury awarded Mylan $106.7 million in damages, the generic
drug maker said.
The case was related to 2007 agreements between Glaxo and Mylan
regarding extended-release tablets of antidepressant paroxetine
hydrochloride. Under the agreements, Mylan said it obtained certain
intellectual property rights from Glaxo.
"Mylan is pleased with the jury verdict and intends to seek
additional relief to further protect its rights," Mylan said.
A Glaxo representative didn't immediately respond to a request
for comment.
Shares of Mylan and Glaxo were inactive premarket.
Write to Michael Calia at michael.calia@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires